Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects

References

• Rodriguez F, Maron DJ, Knowles JW, et al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017 Jan 1;2(1):47–54.
   Google Scholar
• Ford I, Murray H, McCowan C, et al. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of west of scotland coronary prevention study. Circulation. 2016 Mar 15;133(11):1073–1080.
   Google Scholar
• Mach F, Baigent C, Catapano AL. Authors/Task Force M, Guidelines ESCCfP, Societies ESCNC. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140–205.
   Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/american heart association task force on practice guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1–45.
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 Oct 8;366(9493):1267–1278.
   Google Scholar
• Cholesterol Treatment Trialists C, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015 Apr 11;385(9976):1397–1405.
   Google Scholar
• Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019Feb2;393(10170):407–415.
   Google Scholar
• Cholesterol Treatment Trialists C, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012 Aug 11;380(9841):581–590.
   Google Scholar
• Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 Nov 13;376(9753):1670–1681.
   Google Scholar
• Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018 Apr 17;319(15):1566–1579.
   Google Scholar
• Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017 Oct 28;390(10106):1962–1971.
   Google Scholar
• Chou R, Dana T, Blazina I, et al. Statins for prevention of cardiovascular disease in adults: evidence report and systematic review for the US preventive services task force. JAMA. 2016 Nov 15;316(19):2008–2024.
   Google Scholar
• Alter DA, Tu JV, Koh M, et al. Projected real-world effectiveness of using aggressive low-density lipoprotein cholesterol targets among elderly statin users following acute coronary syndromes in Canada. J Am Heart Assoc. 2018 May 12;7(10). DOI:10.1161/JAHA.117.007535.
   Google Scholar
• Danchin N, Almahmeed W, Al-Rasadi K, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the international cholesterol management practice study (ICLPS). Eur J Prev Cardiol. 2018 Jul;25(10):1087–1094.
   Google Scholar
• Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the return on expenditure achieved for lipid therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008 Jul;24(7):1951–1963.
   Google Scholar
• Yan BP, Chiang FT, Ambegaonkar B, et al. Low-density lipoprotein cholesterol target achievement in patients surviving an acute coronary syndrome in Hong Kong and Taiwan - findings from the dyslipidemia international study II. Int J Cardiol. 2018 Aug;15(265):1–5.
   Google Scholar
• Petrov I, Dumitrescu A, Snejdrlova M, et al. Clinical management of high and very high risk patients with Hyperlipidaemia in Central and Eastern Europe: an observational study. Adv Ther. 2019 Mar;36(3):608–620.
   Google Scholar
• Chen WJ, Wen YC, Fox KM, et al. Treatment patterns of lipid-lowering therapies and possible statin intolerance among statin users with clinical atherosclerotic cardiovascular disease (ASCVD) or diabetes mellitus (DM) in Taiwan. J Eval Clin Pract. 2019 Oct 23. DOI:10.1111/jep.13286.
   Google Scholar
• Bradley CK, Wang TY, Li S, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019 Apr 2;8(7):e011765.
   Google Scholar
• Jacobson TA, Cheeley MK, Jones PH, et al. The statin adverse treatment experience survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019 May - Jun;13(3):415–424.
   Google Scholar
• Mefford MT, Tajeu GS, Tanner RM, et al. Willingness to be reinitiated on a statin (from the reasons for geographic and racial differences in stroke study). Am J Cardiol. 2018 Sep 1;122(5):768–774.
   Google Scholar
• Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016 Mar 14;37(11):908–916.
   Google Scholar
• Silvennoinen R, Turunen JH, Kovanen PT, et al. Attitudes and actions: A survey to assess statin use among Finnish patients with increased risk for cardiovascular events. J Clin Lipidol. 2017 Mar - Apr;11(2):485–494.
   Google Scholar
• Wei MY, Ito MK, Cohen JD, et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013 Sep-Oct;7(5):472–483.
   Google Scholar
• Ofori-Asenso R, Zoungas S, Liew D. Reinitiation of statin therapy after discontinuation: a meta-analysis. Mayo Clin Proc. 2018 May;93(5):666–668.
   Google Scholar
• Harrison TN, Hsu JY, Rosenson RS, et al. Unmet patient need in statin intolerance: the clinical characteristics and management. Cardiovasc Drugs Ther. 2018 Feb;32(1):29–36.
   Google Scholar
• Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013 Sep;166(3):597–603.
   Google Scholar
• Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013 Apr 2;158(7):526–534.
   Google Scholar
• Roh JW, Chun KH, Kang M, et al. PRavastatin versus FlUVastatin after statin intolerance: the PRUV-intolerance study with propensity score matching. Am J Med. 2019 Nov;132(11):1320–26 e1.
   Google Scholar
• Vonbank A, Drexel H, Agewall S, et al. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. Eur Heart J Cardiovasc Pharmacother. 2018 Oct 1;4(4):230–236.
   Google Scholar
• Nanna MG, Navar AM, Wang TY, et al. Statin use and adverse effects among adults >75 years of age: insights from the patient and provider assessment of lipid management (PALM) registry. J Am Heart Assoc. 2018 May 8;7:10.
   Google Scholar
• Zhou Z, Albarqouni L, Curtis AJ, et al. The safety and tolerability of statin therapy in primary prevention in older adults: a systematic review and meta-analysis. Drugs Aging. 2020 Mar;37(3):175–185.
   Google Scholar
• Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015 Sep;80(3):363–371.
   Google Scholar
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 Jan;31(1):CD004816.
   Google Scholar
• Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the anglo-scandinavian cardiac outcomes trial-lipid-lowering arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet. 2017 Jun 24;389(10088):2473–2481.
   Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovasc Drugs Ther. 2005 Dec;19(6):403–414.
   Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015 Nov-Dec;9(6):758–769.
   Google Scholar
• Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016 Apr 19;315(15):1580–1590.
   Google Scholar
• Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: canadian consensus working group update (2016). Can J Cardiol. 2016 Jul;32(7 Suppl):S35–65.
   Google Scholar
• Guyton JR, Bays HE, Grundy SM, et al. The national lipid association statin intolerance p. an assessment by the statin intolerance panel: 2014 update. J Clin Lipidol. 2014 May-Jun;8(3 Suppl):S72–81.
   Google Scholar
• Chien SC, Chen PS, Huang YH, et al. 2019 Taiwan society of lipids and atherosclerosis expert consensus statement on statin intolerance. J Formos Med Assoc. 2019 Oct;118(10):1385–1392.
   Google Scholar
• Kajinami K, Tsukamoto K, Koba S, et al. Statin intolerance clinical guide 2018. J Atheroscler Thromb. 2019 Oct 4.
   Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid expert panel. Arch Med Sci. 2015 Mar 16;11(1):1–23.
   Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015 May 1;36(17):1012–1022.
   Google Scholar
• Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on expert consensus decision pathways. J Am Coll Cardiol. 2017 Oct 3;70(14):1785–1822.
   Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the american heart association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38–e81.
   Google Scholar
• Gulizia MM, Colivicchi F, Arca M, et al. ANMCO position paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance. Eur Heart J Suppl. 2017 May;19(SupplD):D55–D63.
   Google Scholar
• Force USPST, Bibbins-Domingo K, Grossman DC, et al. Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement. JAMA. 2016 Nov 15;316(19):1997–2007.
   Google Scholar
• Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother. 2012 Aug;10(4):264–271.
   Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016 Nov 19;388(10059):2532–2561.
   Google Scholar
• Ziff OJ, Banerjee G, Ambler G, et al. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):75–83.
   Google Scholar
• Zhu XC, Dai WZ, Ma T. Overview the effect of statin therapy on dementia risk, cognitive changes and its pathologic change: a systematic review and meta-analysis. Ann Transl Med. 2018 Nov;6(22):435.
   Google Scholar
• Poly TN, Islam MM, Walther BA, et al. Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology. 2019;1:1–13.
   Google Scholar
• Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018 Jul 14;39(27):2526–2539.
   Google Scholar
• Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American college of cardiology, American heart association, and national heart, lung and blood institute would appreciate the following citation format: pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).. J Am Coll Cardiol. 2002 Aug 7;40(3):567–572.
   Google Scholar
• Mansi I, Frei CR, Pugh MJ, et al. Statins and musculoskeletal conditions, arthropathies, and injuries. JAMA Intern Med. 2013 Jul 22;173(14):1–10.
   Google Scholar
• Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med. 2012 Feb;125(2):176–182.
   Google Scholar
• Macedo AF, Taylor FC, Casas JP, et al. Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 2014 Mar;22(12):51.
   Google Scholar
• Group MBHPSC, Armitage J, Bowman L, et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol. 2009 Mar 31;9:6.
   Google Scholar
• Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014 Jul;168(1):6–15.
   Google Scholar
• Irwin JC, Khalesi S, Fenning AS, et al. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacol Res. 2018 Feb;128:264–273.
   Google Scholar
• Cholesterol Treatment Trialists C. Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. Am Heart J. 2016 Jun;176:63–69.
   Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390–399.
   Google Scholar
• Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006 Dec 19;114(25):2788–2797.
   Google Scholar
• Rengo JL, Callahan DM, Savage PD, et al. Skeletal muscle ultrastructure and function in statin-tolerant individuals. Muscle Nerve. 2016 Feb;53(2):242–251.
   Google Scholar
• Ballard KD, Parker BA, Capizzi JA, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013 Sep;230(1):121–124.
   Google Scholar
• Turner RM, Pirmohamed M. Statin-related myotoxicity: a comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. J Clin Med. 2019 Dec 20;9(1):22.
   Google Scholar
• Kim WH, Lee CH, Han JH, et al. C/EBP homologous protein deficiency inhibits statin-induced myotoxicity. Biochem Biophys Res Commun. 2019 Jan 15;508(3):857–863.
   Google Scholar
• Knauer MJ, Urquhart BL, Meyer Zu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res. 2010 Feb 5;106(2):297–306.
   Google Scholar
• Sirvent P, Bordenave S, Vermaelen M, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005 Dec 23;338(3):1426–1434.
   Google Scholar
• Rosenson RS, Miller K, Bayliss M, et al. The statin-associated muscle symptom clinical index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017 Apr;31(2):179–186.
   Google Scholar
• Lee HJ, Min CH, Choi KS, et al. Effects of lovastatin(mevacor®) on lowering plasma lipids in patients with hyperlipidemia. Korean Circ J. 1991 8;21(4):781–785.
   Google Scholar
• Bae J-H Dr., Choue C, Kim K, et al. Hypolipidemic Effects and Safety of Lovastatin in Patients with Primary Hypercholesterolemia. Korean Circ J. 1991 Jan 1;21(1):129.
   Google Scholar
• Hosomi N, Nagai Y, Kohriyama T, et al. The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study. EBioMedicine. 2015 Sep;2(9):1071–1078.
   Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006 Sep 30;368(9542):1155–1163.
   Google Scholar
• Saito Y, Shirai K, Sasaki N, et al. Committee of the chiba lipid intervention program s. prognosis of hypercholesterolemic patients taking pravastatin for five years: the chiba lipid intervention program (CLIP) study. J Atheroscler Thromb. 2002;9(2):99–108.
   Google Scholar
• Taguchi I, Iimuro S, Iwata H, et al. High-dose versus low-dose pitavastatin in japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation. 2018 May 8;137(19):1997–2009.
   Google Scholar
• Koizumi J, Shimizu M, Miyamoto S, et al. Effect of pravastatin-induced LDL-cholesterol reduction on coronary heart disease and cerebrovascular disease in Japanese: hokuriku lipid coronary heart disease study-pravastatin atherosclerosis trial (Holicos-PAT). J Atheroscler Thromb. 2002;9(5):251–259.
   Google Scholar
• Mabuchi H, Kita T, Matsuzaki M, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia and coronary heart disease: secondary prevention cohort study of the Japan lipid intervention trial (J-LIT). Circ J. 2002 Dec;66(12):1096–1100.
   Google Scholar
• Strandberg TE, Feely J, Sigurdsson EL, et al. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther. 2004 Nov;26(11):1821–1833.
   Google Scholar
• Rhee EJ, Kim HC, Kim JH, et al. 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med. 2019 Jul;34(4):723–771.
   Google Scholar
• Saito Y, Goto Y, Dane A, et al. Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. J Atheroscler Thromb. 2003;10(6):329–336.
   Google Scholar
• Wu CC, Sy R, Tanphaichitr V, et al. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol–a multinational, multicenter, double-blind study. J Formos Med Assoc. 2002 Jul;101(7):478–487.
   Google Scholar
• Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004 Oct;44(10):1083–1105.
   Google Scholar
• Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005 Oct;78(4):330–341.
   Google Scholar
• Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007 Feb 1;99(3):410–414.
   Google Scholar
• Nagar SP, Rane PP, Fox KM, et al. Treatment patterns, statin intolerance, and subsequent cardiovascular events among Japanese patients with high cardiovascular risk initiating statin therapy. Circ J. 2018 Mar 23;82(4):1008–1016.
   Google Scholar
• Kim S, Han S, Rane PP, et al. Achievement of the low-density lipoprotein cholesterol goal among patients with dyslipidemia in South Korea. PLoS One. 2020;15(1):e0228472.
   Google Scholar
• Wang X, He Y, Wang T, et al. Lipid-lowering therapy and low-density lipoprotein cholesterol (ldl-c) goal achievement in high-cardiovascular-risk patients in Fuzhou, China. J Cardiovasc Pharmacol Ther. 2020;10:1074248419899298.
   Google Scholar
• Bae HJ, Cho YK, Park HS, et al. Early efficacy and safety of statin therapy in Korean patients with hypercholesterolemia: daegu and Gyeongbuk statin registry. Korean J Intern Med. 2020 Mar;35(2):342–350.
   Google Scholar
• Matsuzawa Y, Kita T, Mabuchi H, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J. 2003 Apr;67(4):287–294.
   Google Scholar
• Kim SH, Seo MK, Yoon MH, et al. Assessment of the efficacy and tolerability of 2 formulations of atorvastatin in Korean adults with hypercholesterolemia: a multicenter, prospective, open-label, randomized trial. Clin Ther. 2013 Jan;35(1):77–86.
   Google Scholar
• Kim SH, Park K, Hong SJ, et al. Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clin Ther. 2010 Oct;32(11):1896–1905.
   Google Scholar
• Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007 Nov;29(11):2365–2373.
   Google Scholar
• Kinoshita M, Yokote K, Arai H, et al. Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb. 2018 Sep 1;25(9):846–984.
   Google Scholar
• Task Force on Chinese Guidelines for the Prevention of Cardiovascular D, Editorial Board of Chinese Journal of C. Chinese guidelines for the prevention of cardiovascular diseases(2017). Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Jan 24;46(1): 10–25.
   Google Scholar
• Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther. 2006 Jun;28(6):933–942.
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487–497.
   Google Scholar
• Awad K, Mikhailidis DP, Toth PP, et al. Efficacy and safety of alternate-day versus daily dosing of statins: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2017 Aug;31(4):419–431.
   Google Scholar
• Muhammad ZA, Ahmad T, Baloch N. Can alternate-day statin regimen minimize its adverse effects on muscle and tendon? A systematic review. J Pak Med Assoc. 2019 Jul;69(7):1006–1013.
   Google Scholar
• Backes JM, Moriarty PM, Ruisinger JF, et al. Effects of Once Weekly Rosuvastatin Among Patients With a Prior Statin Intolerance††Conflicts of interest: dr. Backes is with the Speakers Bureau of Abbott Labs, Abbott Park, Illinois. Dr. Moriarty receives research funding from and is a consultant for B Braun. Dr. Moriarty has also been a consultant for sanofi aventis, Bridgewater, New Jersey, and Reliant Pharmaceuticals, Liberty Corner, New Jersey; with the Speakers Bureaus of Astra Zeneca, Wilmington, Delaware; Abbott Labs, Abbott Park, Illinois; Merck/Schering-Plough, Whitehouse Station, New Jersey, and Takeda Pharmaceuticals, Deerfield, Illinois; and has performed contracted research for Kos Pharmaceuticals, Abbott Park, Illinois; sanofi aventis; Novartis, Basel, Switzerland, HELP Inc., Dover, Delaware; and Kaneka, NY, NY.. Am J Cardiol. 2007 Aug 1;100(3):554–555.
   Google Scholar
• Gadarla M, Kearns AK, Thompson PD. Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008 Jun 15;101(12):1747–1748.
   Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018 Nov 29;379(22):2097–2107.
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713–1722.
   Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–2397.
   Google Scholar
• Cho L, Dent R, Stroes ESG, et al. Persistent safety and efficacy of evolocumab in patients with statin intolerance: a subset analysis of the OSLER open-label extension studies. Cardiovasc Drugs Ther. 2018 Aug;32(4):365–372.
   Google Scholar
• Guedeney P, Giustino G, Sorrentino S, et al. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J. 2019 Jul 3.
   Google Scholar
• Savarese G, De Ferrari GM, Rosano GM, et al. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015 Dec;15(201):247–252.
   Google Scholar
• Bove M, Cicero AFG, Borghi C. Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019 Mar;24(1):63–69.
   Google Scholar
• Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015 May 14;36(19):1186–1194.
   Google Scholar
• Strilchuk L, Fogacci F, Cicero AF. Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data. Expert Opin Drug Saf. 2019 Jul;18(7):611–621.
   Google Scholar
• Yu M, Liang C, Kong Q, et al. Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids Health Dis. 2020 Jan 4;19(1):1.
   Google Scholar
• Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018 Jul 3;72(1):96–118.
   Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999–3058.
   Google Scholar
• Gerards MC, Terlou RJ, Yu H, et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis. 2015 Jun;240(2):415–423.
   Google Scholar
• Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019 May;143:1–16.
   Google Scholar
• Feng D, Ge C, Tan ZY, et al. Isoflavones enhance pharmacokinetic exposure of active lovastatin acid via the upregulation of carboxylesterase in high-fat diet mice after oral administration of Xuezhikang capsules. Acta Pharmacol Sin. 2018 Nov;39(11):1804–1815.
   Google Scholar
• Joint committee for guideline r. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018 Jan;15(1):1–29.
   Google Scholar
• Zhang LS, Zhang JH, Feng R, et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med. 2019;47(4):751–767.
   Google Scholar
• Ju J, Li J, Lin Q, et al. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018 Nov;15(50):25–34.
   Google Scholar
• Cicero AFG, Colletti A, Bajraktari G, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017 Aug;13(5):965–1005.
   Google Scholar
• Meng S, Wang LS, Huang ZQ, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2012 May;39(5):406–411.
   Google Scholar
• Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69–81.
   Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019 Nov 12;322(18):1780–1788.
   Google Scholar